Aerocrine net sales increase 10 percent to SEK 93.

October – December 2011 Net sales grew by 35 percent to SEK 29.1m .7m , corresponding to a loss per share before dilution of SEK 0.5 Aerocrine’s FeNO technology is regular practice in NHANES data by the CDC, Middle of Disease Control, to define airway inflammation in US population. An EGM was held on November 16th where it had been decided to put into action a fresh incentive program and also electing Thomas Eklund as a fresh person in the board. Significant occasions after the period The revised reimbursement strategy continued to show positive momentum with a continued increase of covered lives by general public and private payers in the US as several payers changed their plans and are now reimbursing doctors for using FeNO.At ESTRO, Accuray will showcase: The brand new Delivery Analysis Software program for the TomoTherapy System: added confidence for each and every patient, every fraction, through a fresh tool that provides unprecedented usage of treatment delivery information. Multiple educational opportunities: thought leaders discuss adjustments in radiation therapy treatments over the last 30 years during our satellite television symposium – titled Radiation Therapy: Connecting History, Innovation and Patients. Clinical evidence for both CyberKnife and TomoTherapy Systems: usage of 100 presentations/posters is on the ESTRO website.